The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.a

Bronchospasm - Wheezing - Asthma

Publications

Uyanikoglu A, Ermis F, Akyuz F, Pinarbasi B, Baran B, Aydogan T, Demir K, Besisik F, Kaymakoglu S

Infliximab in inflammatory bowel disease: attention to adverse events.

European review for medical and pharmacological sciences 2014 Aug;18;2337-42 — 2014 Aug — 2337-42

Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S

Asthma unmasked with tumor necrosis factor-?-blocking drugs.

Chest 2011 Oct;140;1068-1071 — 2011 Oct — 1068-1071

Dubey S, Kerrigan N, Mills K, Scott DG

Bronchospasm associated with anti-TNF treatment.

Clinical rheumatology 2009 Aug;28;989-92 — 2009 Aug — 989-92